The Survey highlighted that Indian pharmaceutical exports achieved a healthy growth of 24 per cent in FY21 and expressed hope that India’s domestic pharmaceutical market is estimated to grow to US $65 billion by 2024 from estimated US $41 billion in 2021
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
The Durezol brand and generic had US sales of approximately US $40 million MAT for the most recent twelve months ending in Nov 2022 according to IQVIA
Multilateral collaborations will serve to strengthen knowledge sharing to formulate framework for accessible, affordable, and quality healthcare
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
This DSIR recognition for company's in-house R&D Unit make it eligible for receiving funds for R&D purpose from various government departments and agencies
The cardiomyopathies market in the 68M is set to grow at a CAGR of 12.1%
Purchase agreement with ViewRay will make state-of-the art precision radiation therapy available in China
Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules
Passengers arriving from 6 high-risk countries are now mandatorily required to upload their negative RT-PCR test
Subscribe To Our Newsletter & Stay Updated
